action of glp 1 agonist Frontiers Frontiers | Exploring the multifaceted

How many people take GLP-1 medications

Compared with other second- or third-line glucose-lowering medications, the GLP-1RAs demonstrated a lower rate of adverse CVEs, including heart failure (HR 0.88

- **Slow digestion:** Delaying stomach emptying to prevent spikes in sugar levels after meals

Stratified analyses showed no differences between subgroups

The GLP-1 drugs market size is predicted to grow from USD 58.05 billion in 2026 to USD 132.79 billion by 2035, driven by a CAGR of 9.63%.

A newly published clinical investigation in the British Journal of Anaesthesia (May 2025 issue) reveals compelling evidence linking glucagon-like peptide-1 receptor agonists (GLP-1RAs) to impaired gastric emptying (IGE)